AQST

Peers: SUPN PRGO ALKS BHC INDV AMRX TEVA VTRS LNTH HRMY

| Held by: IWM VTI XPH VXF IWN VTWO IWO IWC SURI FSCC

Index	RUT
Market Cap	591.16M
Enterprise Value	641.76M
Income	-78.23M
Sales	54.09M
Book/sh	-0.45
Cash/sh	0.78
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	147
IPO	Jul 25, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	10.93
P/B	-
P/C	6.00
P/FCF	-
EV/EBITDA	-
EV/Sales	11.86
Quick Ratio	6.74
Current Ratio	7.19
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-0.65
EPS next Y	-0.50
EPS next Q	-0.12
EPS this Y	37.04%
EPS next Y	-1.81%
EPS next 5Y	21.87%
EPS past 3/5Y	11.13% 13.92%
Sales past 3/5Y	-2.24% -0.58%
EPS Y/Y TTM	5.86%
Sales Y/Y TTM	22.56%
EPS Q/Q	-34.09%
Sales Q/Q	38.15%
Earnings	Aug 11 AMC
EPS/Sales Surpr.	-71.43% 21.03%

Insider Own	5.22%
Insider Trans	-7.14%
Inst Own	55.28%
Inst Trans	0.09%
ROA	-69.29%
ROE	-
ROIC	-86.35%
Gross Margin	67.04%
Oper. Margin	-97.52%
Profit Margin	-144.63%
SMA20	12.88%
SMA50	12.34%
SMA200	5.12%
Trades

Shs Outstand	125.51M
Shs Float	118.96M
Short Float	15.17%
Short Ratio	7.18
Short Interest	18.05M
52W High	7.55 -37.62%
52W Low	2.93 60.75%
Volatility	5.84% 5.70%
ATR (14)	0.24
RSI (14)	66.18
Beta	1.45
Rel Volume	0.00
Avg Volume	2.51M
Volume	102

Perf Week	9.03%
Perf Month	26.27%
Perf Quarter	15.44%
Perf Half Y	15.16%
Perf YTD	-27.09%
Perf Year	22.02%
Perf 3Y	163.13%
Perf 5Y	18.64%
Perf 10Y	-
Recom	1.00
Target Price	9.33
Prev Close	4.80
Price	4.71
Change %	-1.88%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-24-26	Resumed	Oppenheimer	Outperform	$8
Jun-02-25	Resumed	Oppenheimer	Outperform	$7
Dec-17-24	Initiated	Cantor Fitzgerald	Overweight	$17
May-10-24	Initiated	Leerink Partners	Outperform	$8
Apr-11-24	Initiated	Piper Sandler	Overweight	$10
Mar-28-24	Initiated	Raymond James	Outperform	$7
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$7
Apr-22-19	Initiated	H.C. Wainwright	Buy
Jan-03-19	Initiated	Lake Street	Buy	$14
Aug-20-18	Initiated	RBC Capital Mkts	Outperform	$23
Aug-20-18	Initiated	JMP Securities	Mkt Outperform	$29

Show Previous Ratings

Aug-12-26 07:04PM	Aquestive Therapeutics Inc (AQST) (Q2 2026) Earnings Call Highlights: Anaphylm Resubmission on ... (GuruFocus.com)
08:30AM	Aquestive Therapeutics, Inc. Q2 2026 Earnings Call Summary (Moby)
Aug-11-26 04:22PM	Aquestive Therapeutics: Q2 Earnings Snapshot (Associated Press)
04:01PM	Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
09:21AM	Earnings To Watch: Aquestive Therapeutics Inc (AQST) Q2 2026 -- GF Value Sees 40% Downside (GuruFocus.com)
10:24AM	Loading…
Aug-10-26 10:24AM	Aquestive Therapeutics shares jump after encouraging Anaphylm study results (InvestorsHub) +8.88%
09:20AM	Earnings To Watch: Aquestive Therapeutics Inc (AQST) Q2 2026 -- GF Value Sees 35% Downside (GuruFocus.com)
07:00AM	Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm (dibutepinephrine) Sublingual Film (GlobeNewswire)
Jul-29-26 07:00AM	Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET (GlobeNewswire)
Jul-07-26 07:00AM	Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism (GlobeNewswire)
Jun-23-26 03:00AM	Does US manufacturing give drugmakers a speed edge? (Pharma Voice) +6.57%
May-14-26 07:03PM	Aquestive Therapeutics Inc (AQST) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com) +14.53% -11.84%
May-13-26 04:10PM	Aquestive Therapeutics: Q1 Earnings Snapshot (Associated Press)
04:01PM	Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
May-12-26 09:31AM	Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree (GlobeNewswire)
07:00AM	Loading…
May-06-26 07:00AM	Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET (GlobeNewswire)
Mar-30-26 07:00AM	Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm (dibutepinephrine) Sublingual Film (GlobeNewswire)
Mar-26-26 09:00AM	AQST Lawsuit Alleges Allegedly Concealed Anaphylm NDA Deficiencies - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Allegedly Concealed Anaphylm NDA Deficiencies: SueWallSt (PR Newswire)
Mar-20-26 07:00AM	Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer (GlobeNewswire)
Mar-12-26 09:00AM	AQST Lawsuit Alleges Analyst Slashed Price Target - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Analyst Slashed Price Target: SueWallSt (PR Newswire) -5.62%
Mar-09-26 04:01PM	Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-05-26 06:47PM	Aquestive Therapeutics Q4 Earnings Call Highlights (MarketBeat)
02:01PM	Aquestive Therapeutics Inc (AQST) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst Legal ... (GuruFocus.com)
08:30AM	Aquestive Therapeutics, Inc. Q4 2025 Earnings Call Summary (Moby)
Mar-04-26 06:30PM	Compared to Estimates, Aquestive Therapeutics (AQST) Q4 Earnings: A Look at Key Metrics (Zacks) +6.07%
05:15PM	Aquestive Therapeutics (AQST) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:25PM	Aquestive Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
07:20AM	Aquestive Therapeutics Inc (AQST) Q4 2025 Earnings Report Preview: What to Look For (GuruFocus.com)
Mar-03-26 07:19AM	Aquestive Therapeutics Inc (AQST) Q4 2025: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
06:00PM	Loading…
Mar-02-26 06:00PM	Harrow (HROW) Misses Q4 Earnings Estimates (Zacks) +5.25%
Feb-26-26 03:48PM	Aquestive Therapeutics Touts Anaphylm, Targets Q3 FDA Resubmission After CRL at Oppenheimer Conference (MarketBeat)
Feb-25-26 07:00AM	Aquestive Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-24-26 07:00AM	Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET (GlobeNewswire)
Feb-23-26 04:33PM	Lake Street Adjusts Aquestive Therapeutics, Inc. (AQST) Valuation Model on Expected Approval Delay (Insider Monkey)
07:00AM	Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Feb-20-26 07:00AM	Aquestive Therapeutics to Present New Clinical Data on Anaphylm (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting (GlobeNewswire)
Feb-18-26 07:00AM	Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer (GlobeNewswire)
Feb-04-26 08:46AM	Aquestive Therapeutics price target lowered to $6 from $8 at Lake Street (TipRanks)
Feb-03-26 10:45AM	Leerink sees silver lining in Aquestive CRL given defined path to approval (TipRanks)
05:50AM	Aquestive receives FDA CRL for Anaphylm allergic reaction treatment (Pharmaceutical Technology)
Feb-02-26 05:17PM	Health Care Roundup: Market Talk (The Wall Street Journal) +38.98%
01:12PM	What's Going On With Aquestive Therapeutics Stock After FDA Update For Lead Allergic Treatment? (Benzinga)
12:52PM	Aquestive Therapeutics Gets FDA CRL for Anaphylm, Eyes Q3 Resubmission After Human Factors Fixes (MarketBeat)
07:00AM	Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm (GlobeNewswire)
Jan-22-26 03:09AM	Jim Cramer on Aquestive Therapeutics: "I'm Not Sure If They Deserve the Benefit of the Doubt" (Insider Monkey)
Jan-14-26 09:55AM	Here's Why Aquestive Therapeutics (AQST) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Jan-12-26 09:09PM	Lightning Round: Sony is a buy here, says Jim Cramer (CNBC TV) -10.23%
09:35AM	Down 37% in 4 Weeks, Here's Why Aquestive Therapeutics (AQST) Looks Ripe for a Turnaround (Zacks)
Jan-10-26 09:00AM	Morning Movers: Oklo, Vistra climb following Meta nuclear energy deals (TipRanks)
Jan-09-26 12:32PM	Bad News For Competitor Turns Into Big Win For ARS Pharma Stock (Benzinga) -37.04%
11:28AM	Aquestive Stock Slides After FDA Flags Issues With Allergy Drug Application (Benzinga)
07:00AM	Aquestive Therapeutics Announces Regulatory Development for Anaphylm (dibutepinephrine) Sublingual Film and Provides Business Update (GlobeNewswire)
Jan-07-26 12:00PM	Aquestive Therapeutics (AQST) Upgraded to Buy: Here's Why (Zacks)
Nov-24-25 07:00AM	Aquestive Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-13-25 12:09PM	Jim Cramer on Aquestive Therapeutics: "I Think It's a Very Interesting Spec" (Insider Monkey) -5.02%
Nov-11-25 08:35PM	Lightning Round: Joby Aviation is losing too much money, says Jim Cramer (CNBC TV)
Nov-06-25 02:09PM	Aquestive Therapeutics Inc (AQST) Q3 2025 Earnings Call Highlights: Navigating Challenges and ... (GuruFocus.com)
Nov-05-25 06:00PM	Here's What Key Metrics Tell Us About Aquestive Therapeutics (AQST) Q3 Earnings (Zacks)
05:35PM	Aquestive Therapeutics (AQST) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:37PM	Aquestive Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Aquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
07:44AM	Aquestive Therapeutics Inc (AQST) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Nov-04-25 08:14AM	Aquestive Therapeutics Inc (AQST) Q3 2025 Earnings Report Preview: What To Look For (GuruFocus.com) -6.32%
07:00AM	Aquestive Therapeutics Announces Leadership Expansion to Support Growth (GlobeNewswire)
Nov-03-25 07:00AM	Aquestive Therapeutics to Participate in a Fireside Chat Hosted by Piper Sandler (GlobeNewswire)
Oct-31-25 09:40AM	Is DBV Technologies (DBVT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-30-25 07:00AM	Aquestive Therapeutics to Attend 2025 ACAAI Annual Meeting (GlobeNewswire)
Oct-27-25 07:00AM	Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET (GlobeNewswire)
Oct-15-25 09:40AM	Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year? (Zacks) +6.69%
Oct-10-25 08:59AM	Aquestive Therapeutics (AQST) Surges 7.9%: Is This an Indication of Further Gains? (Zacks)
Oct-08-25 07:00AM	Aquestive Therapeutics Broadens Patent Estate for Anaphylm (GlobeNewswire)
Sep-22-25 04:37AM	Aquestive Therapeutics (AQST) Soars 14.8%: Is Further Upside Left in the Stock? (Zacks) -8.82%
03:42AM	Jim Cramer on Aquestive Therapeutics: "I think it's Worth Taking a Chance On" (Insider Monkey)
Sep-05-25 11:00AM	AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA (Zacks) +7.11%
Sep-04-25 12:44PM	FDA Confirms Direct Review Path For Aquestive's Allergy Treatment (Benzinga) +28.10%
07:00AM	Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm (GlobeNewswire)
Aug-26-25 07:00AM	Aquestive Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-18-25 06:57AM	Aquestive signs $75m agreement for launch of Anaphylm (Pharmaceutical Technology)
Aug-14-25 09:40AM	Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year? (Zacks)
06:28AM	Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock (GlobeNewswire)
06:00AM	Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm (epinephrine) Sublingual Film (GlobeNewswire)
Aug-11-25 07:30PM	Compared to Estimates, Aquestive Therapeutics (AQST) Q2 Earnings: A Look at Key Metrics (Zacks)
06:55PM	Aquestive Therapeutics (AQST) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
06:07PM	Aquestive Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
09:32AM	Aquestive Therapeutics Inc (AQST) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Aug-08-25 09:25AM	Aquestive Therapeutics Inc (AQST) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Aug-04-25 07:00AM	Aquestive Therapeutics to Report Second Quarter 2025 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET (GlobeNewswire) +5.24%
Jul-22-25 05:20PM	USANA Health Sciences (USNA) Q2 Earnings and Revenues Top Estimates (Zacks) -6.15% +7.30%
07:00AM	Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer (GlobeNewswire)
Jul-15-25 07:00AM	Aquestive Therapeutics Provides International Expansion Update for Anaphylm (epinephrine) Sublingual Film (GlobeNewswire)
Jul-07-25 07:00AM	Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism (GlobeNewswire)
Jul-02-25 10:06PM	H.C. Wainwright Reaffirms Buy on Aquestive Therapeutics, Inc. (AQST) After FDA Approval (Insider Monkey) +8.24%
Jun-25-25 07:00AM	Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit (GlobeNewswire)
Jun-24-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Jun-16-25 07:00AM	Aquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm for the Treatment of Severe Allergic Reactions (GlobeNewswire)
May-21-25 11:17AM	Aquestive Therapeutics, Inc. (AQST): Analysts See 245% Upside Potential (Insider Monkey) -5.02%
May-14-25 03:05AM	Aquestive Therapeutics Inc (AQST) Q1 2025 Earnings Call Highlights: Navigating Revenue Declines ... (GuruFocus.com)
May-12-25 05:30PM	Aquestive Therapeutics (AQST) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks) -19.65%

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients' therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

CEOMr. Daniel Barber

Senior VP & CFOMr. A. Ernest Toth Jr.

Esq.Ms. Lori J. Braender BSBA

Chief Operating OfficerMs. Cassie Jung

Chief Legal Officer & Chief Compliance OfficerMr. Thomas A. Zalewski

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Barber Daniel	President and CEO	Aug 17 '26	Sale	4.29	25,000	107,168	585,574	Aug 18 04:13 PM
Daniel Barber	Officer	Aug 17 '26	Proposed Sale	4.25	25,000	106,250		Aug 17 04:34 PM
Barber Daniel	President and CEO	Jul 16 '26	Sale	4.00	20,369	81,509	610,574	Jul 17 01:15 PM
Barber Daniel	President and CEO	Jul 15 '26	Sale	4.03	4,631	18,683	630,943	Jul 17 01:15 PM
Daniel Barber	Officer	Jul 15 '26	Proposed Sale	4.04	25,000	101,000		Jul 15 04:37 PM
Krop Julie	Director	Jun 23 '26	Option Exercise	0.71	25,000	17,830	25,000	Jun 24 11:11 AM
Krop Julie	Director	Jun 23 '26	Sale	5.02	25,000	125,392	0	Jun 24 11:11 AM
JULIE KROP	Director	Jun 23 '26	Proposed Sale	4.72	25,000	118,000		Jun 23 04:26 PM
Barber Daniel	President and CEO	Jun 15 '26	Sale	4.16	25,000	104,010	635,574	Jun 16 04:09 PM
Daniel Barber	Officer	Jun 15 '26	Proposed Sale	4.17	25,000	104,250		Jun 15 04:38 PM
Barber Daniel	President and CEO	May 15 '26	Sale	4.29	8,257	35,413	660,574	May 18 02:03 PM
Daniel Barber	Officer	May 15 '26	Proposed Sale	4.73	8,257	39,056		May 15 04:32 PM
Boyd Peter E.	Chief People Officer	Mar 10 '26	Sale	4.17	29,814	124,414	338,509	Mar 11 12:52 PM
Barber Daniel	President and CEO	Mar 10 '26	Sale	4.17	180,677	753,965	1,004,753	Mar 11 12:52 PM
BRAENDER LORI J	Chief Legal Officer	Mar 10 '26	Sale	4.17	40,102	167,346	442,879	Mar 11 12:52 PM
Cioffi Melina	SVP, Regulatory Affairs	Mar 10 '26	Sale	4.17	25,311	105,623	274,867	Mar 11 12:52 PM
TOTH A ERNEST JR	Chief Financial Officer	Mar 10 '26	Sale	4.17	58,254	243,094	376,112	Mar 11 12:51 PM
Korczynski Sherry	Chief Commercial Officer	Mar 10 '26	Sale	4.17	15,741	65,687	241,117	Mar 11 12:51 PM
Jung Cassie	Chief Operating Officer	Mar 10 '26	Sale	4.17	45,791	191,086	274,980	Mar 11 12:50 PM
Carl N. Kraus	Affiliate	Nov 17 '25	Proposed Sale	5.39	53,100	286,209		Nov 17 04:39 PM
Jung Cassie	Chief Operating Officer	Oct 15 '25	Option Exercise	3.10	25,000	77,568	308,346	Oct 17 02:01 PM
Jung Cassie	Chief Operating Officer	Oct 15 '25	Sale	7.01	67,575	473,701	240,771	Oct 17 02:01 PM
Kraus Carl N	Chief Medical Officer	Oct 15 '25	Sale	7.00	20,272	141,904	282,475	Oct 17 02:01 PM
Boyd Peter E.	See Remarks	Oct 15 '25	Sale	7.00	10,000	70,000	268,323	Oct 17 02:00 PM
Carl N. Kraus	Officer	Oct 15 '25	Proposed Sale	6.88	40,544	278,943		Oct 15 04:45 PM
CASSIE JUNG	Officer	Oct 15 '25	Proposed Sale	6.88	67,575	464,916		Oct 15 04:34 PM
Peter Boyd	Officer	Oct 15 '25	Proposed Sale	7.00	10,000	70,000		Oct 15 12:24 PM
Barber Daniel	President and CEO	Sep 26 '25	Sale	6.03	91,343	551,191	923,430	Sep 29 04:26 PM
Boyd Peter E.	See Remarks	Sep 26 '25	Sale	6.30	10,000	63,000	278,323	Sep 29 04:26 PM
Peter Boyd	Officer	Sep 26 '25	Proposed Sale	6.30	10,000	63,000		Sep 29 04:05 PM
DANIEL BARBER	Director	Sep 26 '25	Proposed Sale	5.26	91,343	480,464		Sep 26 04:32 PM
Barber Daniel	President and CEO	Sep 19 '25	Sale	6.00	400	2,400	1,014,773	Sep 22 05:25 PM
DANIEL R BARBER	Officer	Sep 19 '25	Proposed Sale	4.94	400	1,976		Sep 19 04:45 PM
Jung Cassie	Chief Operating Officer	Sep 04 '25	Option Exercise	1.93	50,000	96,408	345,526	Sep 08 07:06 PM
Jung Cassie	Chief Operating Officer	Sep 04 '25	Sale	5.00	62,180	310,900	283,346	Sep 08 07:06 PM
Boyd Peter E.	See Remarks	Sep 05 '25	Sale	5.30	15,000	79,500	288,323	Sep 08 05:13 PM
Boyd Peter E.	Officer	Sep 05 '25	Proposed Sale	5.30	15,000	79,500		Sep 05 10:32 AM
CASSIE JUNG	Officer	Sep 04 '25	Proposed Sale	3.95	62,180	245,611		Sep 04 04:26 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Aquestive Therapeutics Inc

Upgrade your Finviz experience